v3.26.1
Segments - Schedule of Segment Revenue and Expenses to Consolidated Net Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Direct research and development expenses by program:            
Selling, general and administrative $ 21,925   $ 15,640   $ 38,093 $ 31,324
Interest income (2,323)   (1,960)   (4,893) (4,191)
Net loss (43,423) $ (41,284) (41,443) $ (35,907) (84,707) (77,350)
Operating Segments [Member]            
Direct research and development expenses by program:            
Personnel-related research and development [1] 9,742   8,207   18,737 16,565
Selling, general and administrative 21,925   15,640   38,093 31,324
Interest income (2,323)   (1,960)   (4,893) (4,191)
Other segment items [2] 53   546   128 881
Net loss (43,423)   (41,443)   (84,707) (77,350)
Operating Segments [Member] | Avexitide            
Direct research and development expenses by program:            
Total direct research and development expenses by program [3],[4] 9,358   7,105   19,348 12,531
Operating Segments [Member] | AMX0035 - PSP            
Direct research and development expenses by program:            
Total direct research and development expenses by program [3],[4] 36   7,146   685 11,709
Operating Segments [Member] | Other programs            
Direct research and development expenses by program:            
Total direct research and development expenses by program [5] $ 4,632   $ 4,759   $ 12,609 $ 8,531
[1] The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs.
[2] Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions.
[3] Depreciation and amortization expense of less than 0.1 million and $0.1 million during the three and six months ended June 30, 2026, respectively, and $0.1 million and $0.3 million during the three and six months ended June 30, 2025, respectively, are allocated across the significant expense captions.
[4] The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the three and six months ended June 30, 2026 and 2025.
[5] Other programs includes milestone payments totaling $4.0 million made to Gubra following the selection and handover of AMX0318 as a development candidate for PBH and other rare diseases during the six months ended June 30, 2026.